TAKEDA PHARMACEUTICAL CO LTD current report, Q4 FY2022

Abrir documento

Takeda Pharmaceutical Co Ltd: Form 6-K Summary

Business Context and Reporting Period

This Form 6-K filing, dated October 27, 2022, presents the Summary of Financial Statements for Takeda Pharmaceutical Company Limited for the six-month period ended September 30, 2022 (Fiscal Year 2022 H1). The company operates globally with listings in Tokyo, Nagoya, Fukuoka, and Sapporo. The financial statements are prepared in accordance with International Financial Reporting Standards (IFRS).

Key Financial Metrics

Metric Value (JPY) YoY Change
Revenue 1,974,771 Million +10.1%
Operating Profit 254,953 Million -26.3%
Profit Before Tax 220,022 Million -22.6%
Net Profit (Period) 166,753 Million -9.2%
Net Profit (Attributable to Owners) 166,756 Million -9.2%
Basic EPS 107.62 JPY -8.1%
Core Operating Profit 625.2 Billion +28.7%
Core EPS 288 JPY +34.6%
Total Assets 14,588,847 Million N/A
Total Equity 6,713,489 Million N/A
Cash & Equivalents 798,137 Million N/A
Net Cash from Operating Activities 305,234 Million -23.9%

Debt and Liquidity: Total bonds and loans increased to 4,736.6 billion JPY, primarily due to foreign currency translation effects. Cash and cash equivalents stood at 798.1 billion JPY as of September 30, 2022.

Material Changes vs. Prior Period

  • Revenue Growth: Reported revenue increased 10.1% year-over-year, driven by business momentum and favorable foreign exchange rates. This growth was partially offset by the absence of a one-time 133.0 billion JPY revenue recognition from the sale of a diabetes portfolio in Japan recorded in the prior year.
  • Operating Profit Decline: Operating profit decreased 26.3% to 255.0 billion JPY. This decline was primarily due to increased amortization and impairment losses on intangible assets (up 33.1%) and higher R&D expenses (up 17.2%), largely impacted by the depreciation of the yen.
  • Therapeutic Area Performance:
    • Growth: Gastroenterology (+27.3%), Rare Diseases (+20.7%), Plasma-Derived Therapies (+31.9%), and Neuroscience (+29.3%) all showed significant growth.
    • Decline: Oncology revenue decreased 3.6% due to rapid generic erosion of VELCADE in the U.S.
  • Core Metrics: Despite the reported operating profit decline, Core Operating Profit increased 28.7% to 625.2 billion JPY, reflecting strong underlying business performance excluding non-recurring items and amortization.

Guidance, Outlook, and Risks

  • Full Year Forecast Revision: Takeda revised its full-year forecast for the fiscal year ending March 31, 2023, upward.
    • Revenue: Revised to 3,930 billion JPY (up 6.5% from original forecast).
    • Operating Profit: Revised to 530 billion JPY (up 1.9% from original forecast).
    • Net Profit: Revised to 307 billion JPY (up 5.1% from original forecast).
  • Management Guidance: The company maintains its guidance for FY2022 Core Growth at Constant Exchange Rate (CER) as: Low-single-digit growth for Core Revenue, and High-single-digit growth for Core Operating Profit and Core EPS.
  • Dividends: An interim dividend of 90 JPY per share was approved, payable December 1, 2022. The annual dividend policy remains 180 JPY per share.
  • Risks and Contingencies:
    • Geopolitical: Takeda has discontinued non-essential activities in Russia but continues to supply patients in Ukraine. Revenue from Russia/CIS represented 1.9% of total revenue in the period.
    • Forex Sensitivity: Results are significantly impacted by foreign exchange rates, particularly the depreciation of the yen.
    • Patent Expirations: Continued generic erosion impacts specific products like VELCADE and PENTASA.

Investor Verification Checklist

  • Core vs. Reported Metrics: Verify the divergence between reported operating profit (down 26.3%) and core operating profit (up 28.7%) to understand the impact of amortization and one-time items.
  • FX Impact: Assess the sensitivity of future earnings to the yen's exchange rate, as the current period benefited significantly from a weaker yen.
  • Oncology Pipeline: Monitor the trajectory of Oncology revenue given the significant drop in VELCADE sales due to generic competition.
  • Debt Redemption: Note the subsequent event of redeeming $1 billion in senior notes in November 2022 and its impact on future interest expenses.
  • Dividend Sustainability: Confirm the ability to maintain the 180 JPY annual dividend given the cash flow dynamics and share buyback activities.